The estimated Net Worth of David J. Arthur is at least $1.02 Миллион dollars as of 26 May 2022. Mr Arthur owns over 43,900 units of Salarius Pharmaceuticals stock worth over $485,718 and over the last 5 years he sold SLRX stock worth over $0. In addition, he makes $530,900 as CEO и Pres & Director at Salarius Pharmaceuticals.
Mr has made over 5 trades of the Salarius Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 43,900 units of SLRX stock worth $7,902 on 26 May 2022.
The largest trade he's ever made was buying 139,488 units of Salarius Pharmaceuticals stock on 3 March 2022 worth over $54,400. On average, Mr trades about 10,082 units every 44 days since 2019. As of 26 May 2022 he still owns at least 303,574 units of Salarius Pharmaceuticals stock.
You can see the complete history of Mr Arthur stock trades at the bottom of the page.
David J. Arthur M.B.A. is the CEO, Pres & Director at Salarius Pharmaceuticals.
As the CEO и Pres & Director of Salarius Pharmaceuticals, the total compensation of Mr A at Salarius Pharmaceuticals is $530,900. There are 1 executives at Salarius Pharmaceuticals getting paid more, with William McVicar having the highest compensation of $1,160,520.
Mr A is 58, he's been the CEO и Pres & Director of Salarius Pharmaceuticals since . There are 5 older and 3 younger executives at Salarius Pharmaceuticals. The oldest executive at Salarius Pharmaceuticals, Inc. is Arnold Hanish, 72, who is the Independent Director.
David's mailing address filed with the SEC is C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOME BLVD., SUITE X, HOUSTON, TX, 77021.
Over the last 5 years, insiders at Salarius Pharmaceuticals have traded over $0 worth of Salarius Pharmaceuticals stock and bought 487,662 units worth $209,636 . The most active insiders traders include David J. Arthur, Mark J Rosenblum и Arnold C Hanish. On average, Salarius Pharmaceuticals executives and independent directors trade stock every 40 days with the average trade being worth of $33,925. The most recent stock trade was executed by Tess Burleson on 7 June 2022, trading 27,700 units of SLRX stock currently worth $4,986.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and potential biomarkers for Seclidemstat (SP-2577). Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Salarius Pharmaceuticals executives and other stock owners filed with the SEC include: